WO2012078317A1 - Methods and compositions useful for promoting sleep in animals - Google Patents
Methods and compositions useful for promoting sleep in animals Download PDFInfo
- Publication number
- WO2012078317A1 WO2012078317A1 PCT/US2011/060597 US2011060597W WO2012078317A1 WO 2012078317 A1 WO2012078317 A1 WO 2012078317A1 US 2011060597 W US2011060597 W US 2011060597W WO 2012078317 A1 WO2012078317 A1 WO 2012078317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sleep
- animal
- promoting
- melatonin
- amount
- Prior art date
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 176
- 241001465754 Metazoa Species 0.000 title claims abstract description 162
- 230000001737 promoting effect Effects 0.000 title claims abstract description 146
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 56
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 100
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 97
- 229960003987 melatonin Drugs 0.000 claims abstract description 97
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000011701 zinc Substances 0.000 claims abstract description 46
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 46
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 35
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 35
- 239000001168 astaxanthin Substances 0.000 claims abstract description 35
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 35
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims description 28
- 230000036541 health Effects 0.000 claims description 19
- 239000000306 component Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 7
- 230000000007 visual effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 229940076279 serotonin Drugs 0.000 claims description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 45
- 241000282472 Canis lupus familiaris Species 0.000 description 36
- 239000005022 packaging material Substances 0.000 description 23
- 235000013305 food Nutrition 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000037213 diet Effects 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 14
- 235000012054 meals Nutrition 0.000 description 11
- 239000013589 supplement Substances 0.000 description 10
- 239000003086 colorant Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000004571 lime Substances 0.000 description 5
- 235000019750 Crude protein Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000019784 crude fat Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 244000089742 Citrus aurantifolia Species 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241001132374 Asta Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- -1 sodium bicarbonate, phosphates Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the inventio relates generally to methods and compositions useful for promoting sleep and part icularly to the use of astaxanthin and melatonin to promote sleep in animals.
- the sleep-wake cycle in animals is the most easily observable eireadian biorhythm. and is an indispensable function of a healthy l ife.
- Normal aging is accompan ied by an increased prevalence in sleep disturbances and decrease in sleep quality.
- As many as 80% f elderly subjects experience difficulty initialing sleep and also show increased night-time wakefulness, early waking, and/or increased daytime napping.
- aging has > been associated with changes in leep patterns and declining activity levels, as commonly reported by pet owners and observed under controlled conditions.
- Increased sleep disturbances or decreased sleep can have deleterious effects, such as decreased cognitive performance like reduced mental acuity and reduced memory, decreased motor skills, and also increased health risks associated with depression, cardiovascular disease, obesity, and/or diabetes.
- (00071 I t is another object of the invention to provide compositions useful for promot ing sleep in senior an imals.
- I t is a further object of the invention to promote the health or wellness of a animal.
- I t is yet another object of the present invention to improve the quality of li fe of an animal.
- One or more of these or other objects are achieved by administering in conjunct ion a sleep promoting amount of astaxanthin and a sleep promoting amount of melatonin to an animal.
- the astaxanthin is administered in an amount ranging from about 0.1 to about 60 nig/kg/body weight of the animal (mg/kg/bw) and the melatonin is administered in an amount ranging from about 0. 1 lo about 40 mg/kg/bw.
- the method can further comprise administering in conjunction a sleep promoting amount of zinc to the an ima l.
- the zinc is admin isiered in an amount ranging from about 1 to about 1 0 m /kg/bw.
- animal' means . mammal capable of sleeping and benefiting from a sleep promoting composition.
- animals can refer to pets such as dogs or cats or other mammals such as humans.
- Containers include, but arc not limited to. bags, boxes, canons, bottles, packages of any type or design or material, over-wrap, shri nk-wrap, affixed components (e.g.. stapled, adhered, or the like), or combinations thereof.
- ⁇ single package may be containers of indi vidual components physical ly assoc iated such that they a reconsidered a unit for manufacture, distribution, sale, or use.
- kits means that the components of a kit are associated by- directions on one or more physical or virtual kit components instructing the user how to obtain the other components, e.g. , a bag or other container containing one component and directions instructing the user to go to a website, contact a recorded message or a fax-back service, view a visual message, or contact a caregiver or instructor to obtain instructions on how to use the kit or safety or technical informat ion about one or more components of a kit.
- 0UUl j The term • "extendi ng the prime' ' means extend ing the number o years an animal lives a healthy life and not just extending the number o years an ani mal lives, e.g.. an animal would be healthy in the prime of its lit for a relatively longer time.
- references “a “ , “air, and “the'” are generally inc lusive of the plurals of the respective terms.
- reference to “a compound' * or ;i a method " includes a plurality of such "compounds '' or “methods. "
- the words “comprise “' , “comprises “ , and ' 'comprising " are to be interpreted inc lusively rather than exclusively.
- the invention provides methods for promoting sleep in an animal.
- the methods comprise administering in conjunction a sleep promoting amount of astaxanthin and a sleep promoting amount of melatonin to the animal .
- the. methods further comprise administering in conjunction a sleep promoting amount of zinc to the animal.
- the astaxanthin. melatonin, and optional zinc can be administered to the animal together or in conjunction in various combinations.
- Admi nistration can be on an as-needed or as-desired basis of varying or regular frequency.
- a goal of regular adm inistration is to provide the animal with a regular and consistent dose of the composition or the direct or indirect metabolites that result from such administration. Such regular and consistent dosing will tend to create constant blood levels of the components of the compositions or their direct or indirect metabol ites.
- regular administration can be once monthly, once weekly, once daily, or more than once daily.
- administration can be every other day, week, or month, every third day, week, or month, every fourth day. week, or month, and the like.
- Admi nistration can be multiple times per day.
- the astaxanthin. melatonin, and optional zinc are administered daily.
- the invention provides a method for promoting the health or wellness of an animal. ' I he method comprises administering in conjunction a health or wellness promoting amount of a combination of astaxanthin and melatonin to the animal. In another aspect, the method further comprises administering in conjunction a health or wellness promoting amount of zinc to the animal.
- the invention provides a method for i mprovi ng the qua lity of li fe of an animal.
- the method comprises administering in conjunction a quality of life improving amount of a combination of astaxanthin and melatonin to the animal.
- the method further comprises administering in conjunction a quality of life improv ing amount of zinc to the animal .
- the invention provides a method for extending the prime years of an animal's li fe.
- the method comprises administering a composition comprisin astaxanthin and melatonin to the animal in an amount effective lor extending the prime years of the animal .
- the niclhod further comprises administering in conjunct ion an amount of zinc in an amount effective for extending the prime years of the animal .
- the astaxanthin and the melatonin can be administered with a meal.
- the astaxanthin and the melatonin can be administered in a liq uid beverage.
- the sleep promoting ingredients can be administered directly to the ani mal, e.g.. orally.
- the sleep promoting ingredients can alternatively be contacted with, or admixed wi th, daily foods or beverages, includ ing a ll uid such as drinking water.
- the astaxanthin and the melatoni n can be adm i yakred at any suitable time or schedule.
- the astaxanthin and the melaton in can be admin istered at a time in the afternoon, in the evening or before a typical bedtime of the animal.
- Administration can also be carried out as part ofa dietary regimen for the animal,
- a dieiary regimen may comprise regular ingestion by the animal of any compound or composition described herein in an amount effective for promoti ng sleep.
- the compounds or compositions arc admin istered to the animal in the evening. c*.£.. between 3 P and 1 0 PM. and/or can be available throughout the evening and overnight.
- the asta.Nanthin can be administered in an amount of from about 0. 1 to about 60 mg/kg/bw including about 5. 1 0. 1 5, 20. 25. 30. 35. 40. 45, 50. 55 mg/kg/bw and the like and any ranges in between.
- the melatonin can be administered in an amount ranging from about 0. 1 to about 40 m g/kg/bw including about 5. 10. 15. 20. 25, 30. 35 mg/kg/bw and the like.
- the astaxanthin can be administered in an amount of from about 0. 1 to about 20 mg/day and the. melatonin is administered in an amount of from about 0. 1 to about 30 mg day.
- the melatonin is adm inistered in an amount of about 0.5. I . 2, 3. 4, 5. 6, 7. 8, 10. 1 2. 14. 1 6. 1 8. and 20 mg/day.
- the astaxanthin is adm inistered in an amou t of about 0.5. I . 2. 3, 4. 5. 6. 7. 8, 1 0. 1 2. 14. 16. 1 8, 20, 22. 24, 26. 28. and 30 mg/day.
- the zinc can be admin istered in an amount ' of rom about 10 to about 100 mg/kg/bw. In various embodiments, the zinc can be administered in an amount of from about 10 to about 100 mg/day. In some embodiments, (be zinc is admin istered to the animal in amounts of from about 0.5 to about 5 limes the recommended daily allowance.
- the animal is a young or growing animal.
- the animal is an aging ani mal or sen ior animal.
- the animal can be susceptible to or suffering from a condition thai i mpairs normal sleep.
- the condition can be jetlag. insomnia, pain, a sleep disorder, etc. (00361 in various embodiments, the method can further comprise administering a sleep aid drug i n conjunct ion with the astaxanthin and the melatonin. I n various embodiments, the method can further comprise administering a hol istic therapy in conjunction with the astaxanthin and the melatonin.
- the invention provides a method for promoting sleep in an animal.
- the method comprises administering in conjunction a sleep promoti ng amount of astaxanthin and one or more melabolizable compounds that can be metabolized to produce melatonin ⁇ the animal .
- the meiliod can further comprise administering in coniunctioii a sleep promoting amount of zinc to the animal.
- the metabolizable compounds arc converted to melatonin by the metabolic processes in the animals, and the melatonin is involved in promoting sleep as described herein.
- the metabolizable compounds are seroton in, tryptophan. 5- hydorxyirypiophan or a combination thereof.
- the metabol izable compounds can be administered in any amount sufficient to obtain the melatonin amounts required herein upon metabolism. Typical ly, the metabolizable compounds are administered in a composition comprising astaxanth in and the metabol izable compounds.
- the invention provides a sleep promoting composition suitable for promoting sleep in an animal.
- the sleep promoting composition includes a sleep promoting amount of astaxanth in and a sleep promoting amount of melatonin combined in die same composition.
- the melatonin can range from about 0. 1 to about 30 mg includ ing about 1 , 2, 3. 4, 5. 6. 7 : 8, 9. 1 0, I I , 1 2. 1 3 , 14, 1 5. 16. 1 7. 1 8. 1 9. 20, 2 1 . 22. 23. 24. 25. 26. 27, 28, 29 mg and th like and any ranges in between.
- the astaxanthin can range from about 0. 1 to about 20 mg including about I , 2, 3, 4, 5, 6, 7, 8, 9, 10. 1 1. 1 2, 1 3, 1 4, 1 5, 16, 17, 18, 19 mg and the like and a y ranges in between .
- Hie sleep promoting composition can further include zinc ranging from about 1 to about 100 mg.
- the invention provi des a sleep promoting composition
- a sleep promoting composition preferably for promoting sleep in an animal .
- the compos ition includes a sleep promoting amount of astaxanthi n and one or more metabolizable compounds that can be metabolized to produce melatonin in the an imal.
- the metabolizable compound can be serotonin, tryptophan, 5- hydorxytryptophan or a combination thereof.
- the sleep promot ing composition can further include zinc ranging from about 10 to about 100 mg.
- the sleep promoting compositions in any embodiments described herein can be, for example, in the form of a snack, a beverage, a pet food composition, a dietary supplement, a pharmaceutical dosage form. etc.
- the sleep promoting compositions can include any suitable ingred ients or components suitable for administering.
- the sleep promoting compositions ean include ingred ient such as. for example, proteins, preservatives, oral care ingredients, visible nutrition, colorants, flavoranis, liumeciants, antioxidants, vitamins, minerals or a combination thereof in any suitable amounts.
- the additional ingredients can further by using to promote a healthy sleep and healthy lifestyle of the animal.
- the protei may be derived from a plant or animal source or both. It may be provided as a protein concentrate. Suitable examples of preservatives include potassium sorbate. sorbic acid, methyl para-hydroxybenzoatc. calcium propionate and propionic acid.
- the oral care ingredients can provide breath freshening and/or tartar control.
- Suitable oral care ingredients include alfalfa nutrient concentrate (contains chlorophyll), sodium bicarbonate, phosphates ⁇ e.g., tricalchim phosphate, acid pyrophosphates, teirasodiiim pyrophosphate, metaphosphates. ort hophosphates). peppermint, c loves, parsley, ginger, etc .
- the visible nutrition ingredients can be in the form of pieces or specks on the surfaces and/or within the sleep promoting compositions. Suitable visible nutrition ingredients include corn germ meal, dehydrated vegetables, fruits, grains ⁇ e.g. , spinach, carrots, cranberry), etc.
- the colorants can provide an aesthetic effect. Suitable colorants inc lude FD & C colors, natural colors, titanium dioxide, etc.
- the flavorants can make the m ulti-textured treat more palatable for the animal .
- Su itable flavorants include yeast, tallow, rendered animal meals ⁇ e.g.. poultry, beef. lamb. pork), flavor extracts or blends (e.g. , gri lled beef), etc.
- Suitable humeciaius include salt, sugars, propylene glycol and polyhydric glycols such as gl ycerin and sorbitol, and the l ike. Suitable antioxidants inc lude HI ⁇ / ⁇ ⁇ ⁇ . vitamin li (tocopherols), etc.
- Suitable vitamins may include Vitamins A, B-complex (such as B- l . B-2, B-6 and B- 12), C, D. E and , niacin and acid vitamins such as pantothenic acid and folic acid and biotin.
- Suitable minerals may include calcium, iron. zinc, magnesium, iodine, copper, phosphorus, manganese, potassium, chromium, molybdenum, selenium, nickel, tin, silicon, vanadium and boron.
- the invent ion provides a kit su itable for promoting sleep or a healthy li estyle in an animal.
- the kit includes in separate containers in a single package or in separate containers in a virtual package, as appropriate for the kit component, one or more of the sleep promoting compositions in any embodiments described herein and one or more of ( I,) a comestible product to be taken in conjunction with the sleep promoting composition. (2) a beverage to be taken i n conjunction with the sleep promoting composition. (3) instructions for how to promote sleep in an animal using the sleep promoting composition. (4) instructions for how to promote sleep in an elderly animal using the sleep promotin composition. (5) instructions for how to promote the health or wellness of an animal using the sleep promoting composition.
- instructions for how to improve the quality of li fe of an animal using the sleep promoting composition (6) instructions for how to improve the quality of li fe of an animal using the sleep promoting composition. (7) instructions for how to extend the prime years of an animal ' s li fe using the sleep promoting composition, or f «S) a sleep toy for an animal.
- the instructions can he suited for spec ific types of animals as well (e.g.. cats. dogs, or humans).
- the kit can be limited to instructions in a virtual environment in combination with one or more physical kit components.
- the kits may contain the kit components in any of various combinations and/or mixtures.
- the kit contains a package containing the steep promotin composition and a comestible product to be taken in conjunction with the sleep promoting composition.
- the kit contains a package containing the sleep promoting composit ion and instructions for how to promote sleep in an animal using the sleep promoting composition.
- the invention provides a means for communicating information about or instructions for using the sleep promoting composition in any embodiments described herein for one or more of ( I ) promoting sleep in an animal; (2) promoting sleep in an elderly animal : (3) promoting the health or wellness of an animal; (4) improving the qua lity of life of an animal; or (5) extending the prime years of an animal ' s li fe, the means comprising a document, digital storage media, optical storage media, audio presentat ion, or visual display contain ing the information or instructions.
- the communication means can be a displayed website, a visual display k iosk, a brochure, a product label, a package insert, an advert isement, a handout, a public announcement, an audiotape, a videotape, a DVD. a CD-ROM, a computer readable chip, a computer readable card, a computer readable disk, a USD device, a PircWi c device, a computer memory, or any combination thereof.
- the communication means is useful for instructing on the benefits of using the sleep promoting composilions and commun icating about the approved methods for using the sleep promoting compositions for an animal.
- the invention provides a use of astaxanthin and melatonin to prepare a sleep promoting composition useful for promoting sleep in an animal.
- the sleep promoting composition further comprises zinc.
- the invention provides an animal food package comprising a container and a plurality of sleep promoting compositions stored within the container.
- the composilions comprising a sleep promoting amount of astaxanthin and a sleep promoting amount of melatonin.
- the package can further include a label affixed to the package
- Such device can include the words "sleep promoting compositions f r animals " or an equivalent expression printed on the package.
- Any package or packaging material suitable for containing sleep promoting compositions is use ful in the invention, e.g.. a bag, box. bottle, can, pouch, and the like manufactured from paper, plastic, foil, metal, and the like.
- the invention provides a method of making a sleep promot ing composition.
- the method comprises adding a sleep promoting amount of asta.xauihiii and a sleep promot ing amount of melatonin to a comestible composition using any suitable manufacturing process known in the art .
- the invention provides for a use of a sleep promot ing amount of astaxanihin and a sleep promoting amount of melatonin to prepare a medicament usclul for promoting sleep, promoting the hea lth or wellness of an animal, improving the quality of life of an animal, and extending the prime years of an animal's l ife.
- medicaments are prepared by admixing the compounds with excipieius, bu ffers, binders, plastici/.ers.
- the medicament further comprises /inc.
- the medicaments contain the compounds in amounts speci f ied herein, e.g.. from about 0. 1 to about 60 mg kg/bw astaxanih in, from about 0. 1 to about 40 mg/kg/bw melatonin, and from about 10 ⁇ about 100 mg/day zinc.
- the invention provides a package useful for containing a sleep promoting amount of astaxanthin and a sleep promoting amount of melaton in, and optionally a sleep promoting amount of zinc.
- the package com prises at least one material suitable for contai ning the compounds and a label affixed to the material containing a word or words, picture, design, acronym, slogan, phrase, or other device, or combination thereof, that indicates that the package contains the compounds and/or their function, e.g.. promoting sleep.
- such device comprises the words " promotes sleep " or " contains natural sleep promoting compounds " or an equ ivalent expressio printed on the materia l.
- the package further comprises at least one window that permit the package contents to be viewed without opening the package.
- the window is a transparent portion of the packaging material.
- the window is a m issing portion of the packaging material.
- Each phase lasted 35 days. Starting on day 29 of each phase, the animals ' locomotor behavioral act ivity was monitored for 4 consecutive days.
- the animals were given supplements of melaton in. Funher, for half of the animals, the supplements were in the morning with the AM feeding and hal f were given in the evening with the PM feeding. Thus, of the 4 males. 2 were administered the melatonin in the morning and two in the evening.
- phase 3 the second control phase, delivery of the methylcellulose in a gel capsule was provided either with the AM or PM feeding, as appropriate to cross-over the treatment from phase 1 -2.
- phase 4 the procedure was exactly the same as phase 2. except thai lor a given animal the supplementation time was switched from phase 2. Thus, if male was administered melatonin in the morning with the AM feeding in phase 2, the male was administered melatonin in the evening with the PM feeding in phase 4.
- Example I Activity data was recorded during the baseline phase of the Example when all dogs were consuming only the control food. After 65 days of the treatment phase, in which dogs svere either on the control or treatment foods, the animals were monitored again for locomotor activity behavior patterns by recording activity data. The monitors recorded activity counts on a 30-sec epoch setting and activity data was downloaded to a PC -computer immediately following the completion of the data recording period for later analysis. Total daily, light phase (day), and dark phase (night) activity counts were generated by the .Act i ware® software provided with the Acliwatch® recording system, along with dark/light phase activity counts ratio.
- the Aciiwarc® software was used to generate total daily, light phase (12-h daytime: 7 am - 7 pm), and dark phase (12-h night-time: 7 P - 7 AM) total sleep or wake minutes.
- Light phase naps represent sleep bouts occurring during the 12-h light phase interval.
- Dark phase wake bouts reflect awake activity during the night-time sleep interval and not the 12-h dark phase interval. Total number of bouts and bout duration were determined for both light phase naps and dark phase awakenings.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2819595A CA2819595A1 (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
EP11847183.8A EP2648513A4 (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
MX2013006353A MX2013006353A (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals. |
US13/991,716 US20130273176A1 (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
JP2013543177A JP2014505031A (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting animal sleep |
AU2011338846A AU2011338846B2 (en) | 2009-09-11 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
RU2013131098/13A RU2594876C2 (en) | 2010-12-07 | 2011-11-14 | Methods and compositions for improving sleep in animals |
CN201180057829XA CN103228139A (en) | 2010-12-07 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
BR112013016554A BR112013016554A2 (en) | 2010-12-07 | 2011-11-14 | methods and compositions useful for promoting sleep in animals |
ZA2013/05086A ZA201305086B (en) | 2010-12-07 | 2013-07-05 | Methods and compositions useful for promoting sleep in animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45918110P | 2010-12-07 | 2010-12-07 | |
US61/459,181 | 2010-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012078317A1 true WO2012078317A1 (en) | 2012-06-14 |
Family
ID=46207452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/060597 WO2012078317A1 (en) | 2009-09-11 | 2011-11-14 | Methods and compositions useful for promoting sleep in animals |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130273176A1 (en) |
EP (1) | EP2648513A4 (en) |
JP (1) | JP2014505031A (en) |
CN (1) | CN103228139A (en) |
AU (1) | AU2011338846B2 (en) |
BR (1) | BR112013016554A2 (en) |
CA (1) | CA2819595A1 (en) |
MX (1) | MX2013006353A (en) |
RU (1) | RU2594876C2 (en) |
WO (1) | WO2012078317A1 (en) |
ZA (1) | ZA201305086B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054651A1 (en) * | 2012-10-03 | 2014-04-10 | 富士フイルム株式会社 | Sleep-improving agent, non-rem sleep time-increasing agent, and sedative agent |
WO2015099102A1 (en) * | 2013-12-27 | 2015-07-02 | 富士フイルム株式会社 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882245A (en) * | 2019-12-16 | 2020-03-17 | 厦门市健康医疗大数据中心(厦门市医药研究所) | Composition for improving sleep and application thereof |
ES2837877A1 (en) * | 2019-12-31 | 2021-07-01 | Laboratorios Vinas S A | GALENIC COMPOSITION, FOR ORAL USE, LIQUID, INCLUDING MELATONIN AND A ZINC SALT AND CORRESPONDING METHOD AND USE (Machine-translation by Google Translate, not legally binding) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091614A1 (en) * | 2000-05-06 | 2003-05-15 | Yoshinobu Kiso | Compositions normalizing circadian rhythm |
US6974841B1 (en) * | 2002-09-27 | 2005-12-13 | Rapisarda Family Irrevocable Trust | Pet anti-aging wellness supplement |
US20080044499A1 (en) * | 2004-04-06 | 2008-02-21 | Taiyokagaku Co., Ltd. | Sleep Improvement Composition |
US20100022636A1 (en) * | 2006-04-04 | 2010-01-28 | Hill's Pet Nutrition, Inc. | Compositions and Methods For Enhancing The Antioxidant Status of Animals |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE228779T1 (en) * | 1999-01-20 | 2002-12-15 | Nutricia Nv | INFANT NUTRITIONAL PREPARATION |
US7211280B1 (en) * | 1999-09-09 | 2007-05-01 | Nestec S.A. | Condition of elderly pets |
US20020120001A1 (en) * | 2000-10-13 | 2002-08-29 | Ashni Naturaceuticals, Inc. | Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect |
US20050249785A1 (en) * | 2003-08-13 | 2005-11-10 | Gordon John G | Use of melatonin-containing oral supplement with animals |
WO2005058064A1 (en) * | 2003-12-19 | 2005-06-30 | Menicon Co., Ltd. | Astaxanthin-containing pet foods |
EP2464350B1 (en) * | 2009-09-11 | 2016-08-24 | Nestec S.A. | Compositions and methods for enhancing cognitive and related functions in animals |
-
2011
- 2011-11-14 RU RU2013131098/13A patent/RU2594876C2/en not_active IP Right Cessation
- 2011-11-14 EP EP11847183.8A patent/EP2648513A4/en not_active Withdrawn
- 2011-11-14 US US13/991,716 patent/US20130273176A1/en not_active Abandoned
- 2011-11-14 JP JP2013543177A patent/JP2014505031A/en active Pending
- 2011-11-14 WO PCT/US2011/060597 patent/WO2012078317A1/en active Application Filing
- 2011-11-14 MX MX2013006353A patent/MX2013006353A/en unknown
- 2011-11-14 CN CN201180057829XA patent/CN103228139A/en active Pending
- 2011-11-14 AU AU2011338846A patent/AU2011338846B2/en not_active Ceased
- 2011-11-14 BR BR112013016554A patent/BR112013016554A2/en not_active IP Right Cessation
- 2011-11-14 CA CA2819595A patent/CA2819595A1/en not_active Abandoned
-
2013
- 2013-07-05 ZA ZA2013/05086A patent/ZA201305086B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091614A1 (en) * | 2000-05-06 | 2003-05-15 | Yoshinobu Kiso | Compositions normalizing circadian rhythm |
US6974841B1 (en) * | 2002-09-27 | 2005-12-13 | Rapisarda Family Irrevocable Trust | Pet anti-aging wellness supplement |
US20080044499A1 (en) * | 2004-04-06 | 2008-02-21 | Taiyokagaku Co., Ltd. | Sleep Improvement Composition |
US20100022636A1 (en) * | 2006-04-04 | 2010-01-28 | Hill's Pet Nutrition, Inc. | Compositions and Methods For Enhancing The Antioxidant Status of Animals |
Non-Patent Citations (1)
Title |
---|
See also references of EP2648513A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054651A1 (en) * | 2012-10-03 | 2014-04-10 | 富士フイルム株式会社 | Sleep-improving agent, non-rem sleep time-increasing agent, and sedative agent |
CN104684583A (en) * | 2012-10-03 | 2015-06-03 | 富士胶片株式会社 | Sleep-improving agent, non-REM sleep time-increasing agent, and sedative agent |
JPWO2014054651A1 (en) * | 2012-10-03 | 2016-08-25 | 富士フイルム株式会社 | Sleep improving agent, non-REM sleep time increasing agent and sedative |
WO2015099102A1 (en) * | 2013-12-27 | 2015-07-02 | 富士フイルム株式会社 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
JPWO2015099102A1 (en) * | 2013-12-27 | 2017-03-23 | 富士フイルム株式会社 | Zinc-containing sleep improving agent, non-REM sleep time increasing agent and sedative |
Also Published As
Publication number | Publication date |
---|---|
CA2819595A1 (en) | 2012-06-14 |
EP2648513A4 (en) | 2014-04-30 |
JP2014505031A (en) | 2014-02-27 |
RU2013131098A (en) | 2015-01-20 |
RU2594876C2 (en) | 2016-08-20 |
AU2011338846A1 (en) | 2013-06-13 |
CN103228139A (en) | 2013-07-31 |
US20130273176A1 (en) | 2013-10-17 |
EP2648513A1 (en) | 2013-10-16 |
AU2011338846B2 (en) | 2016-04-14 |
ZA201305086B (en) | 2014-12-23 |
BR112013016554A2 (en) | 2016-07-12 |
MX2013006353A (en) | 2013-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Saito et al. | Zinc‐rich oysters as well as zinc‐yeast‐and astaxanthin‐enriched food improved sleep efficiency and sleep onset in a randomized controlled trial of healthy individuals | |
US6335361B1 (en) | Method of treating benign forgetfulness | |
RU2605330C2 (en) | Methods and compositions, suitable for improvement of skin health | |
JP5138380B2 (en) | Methods for increasing immune responses in animals | |
EP2869717B1 (en) | Prevention of alcohol reaction with dietary supplements | |
AU2010293065B2 (en) | Compositions and methods for enhancing cognitive and related functions in animals | |
EP2654777A2 (en) | Methods and compositions suitable for managing blood glucose in animals | |
JP2010540636A (en) | Compositions and methods for enhancing cognitive function | |
McBean et al. | Osteoporosis: Visions for care and prevention—A conference report | |
AU2009282482A1 (en) | Methods for enhancing energy metabolism | |
EP2648513A1 (en) | Methods and compositions useful for promoting sleep in animals | |
Tinanoff | Use of fluoride | |
JPWO2008126367A1 (en) | Tranquilizers and functional foods | |
ES2761826T3 (en) | Compositions containing medium chain triglycerides for use in the treatment of epilepsy | |
JP2014519494A (en) | Methods and compositions for promoting increased lean mass | |
US20110162981A1 (en) | Methods and compositions for preventing, reducting or treating damage caused by ischemia and schemia-like conditions | |
JP2014513688A (en) | Method and composition for retaining lean mass during weight loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11847183 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013543177 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2819595 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13991716 Country of ref document: US Ref document number: MX/A/2013/006353 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011338846 Country of ref document: AU Date of ref document: 20111114 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013131098 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013016554 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013016554 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130607 |